PEGylated therapeutic proteins for haemophilia treatment: A review for haemophilia caregivers

Haemophilia

Volumn 19, Issue 1, 2013, Pages 11-20

  Ivens, I A ^a   Baumann, A ^b   McDonald, T A ^a   Humphries, T J ^a   Michaels, L A ^a   Mathew, P ^a  

^a Global Biologics Research   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

ADME; BAY 94 9027; Factor VIII; Haemophilia; PEGylated protein; Safety of PEGylated protein

Indexed keywords

ALDEHYDE DEHYDROGENASE; ASPARAGINASE MACROGOL; BAX 855; BAY 949027; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; MACROGOL; METHOTREXATE; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PEGVISOMANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIGEN PRESENTING CELL; CAREGIVER; CHRONIC HEPATITIS; CROHN DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME METABOLISM; HALF LIFE TIME; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOGENICITY; LOADING DRUG DOSE; MEDLINE; MOLECULAR WEIGHT; MONOTHERAPY; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; THROMBOEMBOLISM;

CAREGIVERS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; POLYETHYLENE GLYCOLS;

EID: 84871015919     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02931.x     Document Type: Review

References (44)

1. Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009; 14: 363-80.
2. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252: 3578-81.
3. Roestin J, Smeds A-L, Akerblom E. B-domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol. Bioconjug Chem 2000; 11: 387-96.
4. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethyleneglycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-77.
5. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Sci 2000; 3: 125-36.
6. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005; 10: 1451-8.
7. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of PEGylation. Drug Delivery 2006; 13: 399-409.
8. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005; 44: 331-47.
9. Harris JM, Robert B, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21.
10. Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 2007; 32: 933-61.
11. Veronese FM, Mero A. The impact of PEGylation on biological therapies 2008. Drug development. Biodrugs 2008; 22: 315-29.
12. Webster R, Didier E, Harris P et al. Minireview: PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007; 35: 9-16.
13. Webster R, Elliott V, Park BK, Walker D, Hankin M, Taupin P. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese FM ed. PEGylated Protein Drugs: Basic Science and Clinical Applications. Switzerland: Birkhäuser Verlag/Switzerland, 2009: 127-46.
14. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010; 5: 113-28.
15. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor phrophylaxis for the hemophilia population: where do we stand?. Hemophilia 2004; 10: 97-104.
16. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
17. FDA. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed January 2012.
18. EMA EPAR. Available at http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true. Accessed January 2012.
19. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon r-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195-202.
20. Davis FF, Kazo GM, Nucci ML, Abuchowski A. Reduction of immunogenicity and extension of circulating half-life of peptides and proteins. In: Lee VHL ed. Peptide and Protein Drug Delivery. Dekker: New York, 1991: 831-64.
21. Ivens IA, Zierz R, Haaning J, McDonald Y. BAY 94-9027, a PEGylated Recombinant Human FVIII, Shows Less Immunogenicity Compared to Un-PEGylated Recombinant FVIII. ASH Ann Meeting Abs 2010; 116: 2214.
22. Young MA, Malavalli A, Winslow N, Vandegriff KD, Winslow RM. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Transl Res 2007; 149: 333-42.
23. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 1998; 42: 152-7.
24. Lin CC, Anseth KS. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm Res 2009; 26: 631-43.
25. Alconcel SNS, Baas AS, Maynard HD. FDA-Approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem 2011; 2: 1442-8.
26. Locatelli F, Mann JF, Aldigier JC et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010; 73: 94-103.
27. Fliser D, Kleophas W, Dellanna F et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010; 26: 1083-9.
28. F, Alarcon C, Azocar M et al. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 2011; 26: 1303-13.
29. Van Cauteren H, Bentley P, Bode G et al. The industry view on long-term toxicology testing in drug development of human pharmaceuticals. Pharmacol Toxicol 2000; 86Suppl 1: 1-5.
30. Horton S, Walsh C, Emery P. 2012 Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012; 12: 235-49.
31. Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology 2011; 50: 261-70.
32. Vavricka SR, Schoepfer AM, Bansky G, Binek J et al. Efficacy and safety of certolizumab pegol in an unselected Crohn's disease population: 26-week data of the FACTS II Survey. Inflamm Bowel Dis 2011; 17: 1530-9.
33. Modi MW, Fulton JS, Buchmann DK, Wright TL, Moore DJ. Clearance of PEGylated (40 kDa) interferon alfa-2a (PEGASYS) is primarily hepatic. Hepatol 2000; 32: 371A.
34. Møss J, Rosenholm A, Lauren A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011; 9: 1368-74.
35. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
36. Dietrich B, Spatzenegger M, Stidl R et al. Safety of Baxter's longer acting rFVIII (BAX 855) after repeated application in rats and Cynomolgus Monkeys. Blood 2011; 118: 21. Abstr #4345.
37. Hemofil M. package insert. Available at http://www.baxter.com/downloads/healthcare/hemofil-m_pi.pdf. Accessed June, 2012.
38. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994; 83: 601-6.
39. Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995; 84: 349-54.
40. Nakaoka R, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 1997; 46: 253-62.
41. Arendshorst WJ, Navar LG. Renal circulation and glomerular hemodynamics. In: Schrier RW, Gottshalk CW eds. Diseases of the Kidney. Boston, MA: Little, Brown, 1988: 65-117.
42. Sherman MR, Williams LD, Saifer MCP, French JA, Kwak LW, Oppenheim JJ. Conjugation of high, molecular weight poly(ethylene glycol) to cytokines: granulocyte-macrophage colony stimulating factors as model substrates. In: Harrris JM, Zalipsky S eds. Poly(Ethylene Glycol): Chemistry and Biological Applications. Washington, DC: ACS, Chapman, 1997: 155-69.
43. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. The low density lipoprotein receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout Studies. Physiol Rev 2008; 88: 887-918.
44. Lenting PJ, VAN Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.